Does the media prefer CTMX or SRPT?

In the previous week, Sarepta Therapeutics had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for Sarepta Therapeutics and 3 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.66 beat CytomX Therapeutics' score of 0.20 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sarepta Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SRPT or EDIT?

In the previous week, Editas Medicine had 30 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 35 mentions for Editas Medicine and 5 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.66 beat Editas Medicine's score of 0.77 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Editas Medicine 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to SRPT or IMVT?

In the previous week, Immunovant had 4 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 9 mentions for Immunovant and 5 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.66 beat Immunovant's score of 0.55 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PCVX or SRPT?

In the previous week, Vaxcyte and Vaxcyte both had 5 articles in the media. Sarepta Therapeutics' average media sentiment score of 1.66 beat Vaxcyte's score of 0.37 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SRPT or LNTH?

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Sarepta Therapeutics and 4 mentions for Lantheus. Sarepta Therapeutics' average media sentiment score of 1.66 beat Lantheus' score of 0.57 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sarepta Therapeutics (SRPT) Competitors

$17.61 -0.26 (-1.45%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$17.73 +0.12 (+0.65%)

As of 06/1/2026 07:59 PM Eastern

Compare

SRPT vs. CTMX, EDIT, IMVT, PCVX, and LNTH

Should you buy Sarepta Therapeutics stock or one of its competitors? MarketBeat compares Sarepta Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Immunovant (IMVT), Vaxcyte (PCVX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sarepta Therapeutics has a net margin of -2.94% compared to CytomX Therapeutics' net margin of -166.40%. Sarepta Therapeutics' return on equity of 7.56% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

CytomX Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

In the previous week, Sarepta Therapeutics had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for Sarepta Therapeutics and 3 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.66 beat CytomX Therapeutics' score of 0.20 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sarepta Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CytomX Therapeutics presently has a consensus target price of $12.10, suggesting a potential upside of 250.72%. Sarepta Therapeutics has a consensus target price of $27.17, suggesting a potential upside of 54.31%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	16.52	-$17.37M	-$0.41	N/A
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A

Summary

CytomX Therapeutics and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Sarepta Therapeutics (NASDAQ:SRPT) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Sarepta Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Editas Medicine has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A
Editas Medicine	$38.69M	8.45	-$160.06M	-$1.23	N/A

Sarepta Therapeutics presently has a consensus target price of $27.17, suggesting a potential upside of 54.31%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 61.68%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sarepta Therapeutics has a net margin of -2.94% compared to Editas Medicine's net margin of -281.59%. Sarepta Therapeutics' return on equity of 7.56% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, Editas Medicine had 30 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 35 mentions for Editas Medicine and 5 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.66 beat Editas Medicine's score of 0.77 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Editas Medicine	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Sarepta Therapeutics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Immunovant?

Sarepta Therapeutics (NASDAQ:SRPT) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Sarepta Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Sarepta Therapeutics currently has a consensus price target of $27.17, suggesting a potential upside of 54.31%. Immunovant has a consensus price target of $37.33, suggesting a potential upside of 13.61%. Given Sarepta Therapeutics' higher possible upside, equities analysts plainly believe Sarepta Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Immunovant had 4 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 9 mentions for Immunovant and 5 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.66 beat Immunovant's score of 0.55 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Immunovant	N/A	-65.66%	-59.88%

Summary

Sarepta Therapeutics beats Immunovant on 9 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Sarepta Therapeutics has higher revenue and earnings than Vaxcyte. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A

Vaxcyte has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Vaxcyte and Vaxcyte both had 5 articles in the media. Sarepta Therapeutics' average media sentiment score of 1.66 beat Vaxcyte's score of 0.37 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 75.83%. Sarepta Therapeutics has a consensus target price of $27.17, suggesting a potential upside of 54.31%. Given Vaxcyte's stronger consensus rating and higher probable upside, research analysts clearly believe Vaxcyte is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11

Vaxcyte has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Summary

Sarepta Therapeutics beats Vaxcyte on 8 of the 14 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Lantheus?

Sarepta Therapeutics (NASDAQ:SRPT) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Sarepta Therapeutics and 4 mentions for Lantheus. Sarepta Therapeutics' average media sentiment score of 1.66 beat Lantheus' score of 0.57 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Sarepta Therapeutics' net margin of -2.94%. Lantheus' return on equity of 29.32% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Lantheus	18.05%	29.32%	15.00%

Lantheus has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A
Lantheus	$1.55B	4.09	$233.56M	$4.15	23.40

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sarepta Therapeutics presently has a consensus price target of $27.17, suggesting a potential upside of 54.31%. Lantheus has a consensus price target of $101.86, suggesting a potential upside of 4.87%. Given Sarepta Therapeutics' higher probable upside, equities analysts plainly believe Sarepta Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

Summary

Lantheus beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.39B	$6.43B	$12.56B
Dividend Yield	N/A	2.28%	2.69%	5.30%
P/E Ratio	-18.34	17.92	21.10	26.63
Price / Sales	0.85	333.00	550.61	112.20
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	1.62	6.84	9.95	6.88
Net Income	-$713.41M	$24.15M	$3.56B	$336.73M
7 Day Performance	5.64%	1.15%	1.62%	3.07%
1 Month Performance	-18.05%	3.78%	6.24%	7.13%
1 Year Performance	-53.34%	58.49%	34.51%	38.42%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.6102 of 5 stars	$17.61 -1.5%	$27.17 +54.3%	-53.3%	$1.89B	$2.20B	N/A	1,372	Positive News
CTMX CytomX Therapeutics	2.4536 of 5 stars	$3.76 flat	$12.10 +221.8%	+36.9%	$639.90M	$76.20M	N/A	170
EDIT Editas Medicine	3.3835 of 5 stars	$2.76 flat	$5.40 +95.7%	+92.5%	$270.22M	$40.52M	N/A	230	Gap Down
IMVT Immunovant	2.0362 of 5 stars	$34.15 flat	$35.33 +3.5%	+121.0%	$7.01B	N/A	N/A	120
PCVX Vaxcyte	2.784 of 5 stars	$47.30 flat	$86.00 +81.8%	+50.0%	$6.83B	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, IMVT, PCVX, and LNTH

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to Immunovant?

Summary

How does Sarepta Therapeutics compare to Vaxcyte?

Summary

How does Sarepta Therapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, IMVT, PCVX, and LNTH

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Do institutionals and insiders hold more shares of CTMX or SRPT?

Is CTMX or SRPT more profitable?

Which has more volatility and risk, CTMX or SRPT?

Does the media prefer CTMX or SRPT?

Do analysts prefer CTMX or SRPT?

Which has higher earnings & valuation, CTMX or SRPT?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Which has more volatility & risk, SRPT or EDIT?

Do institutionals & insiders have more ownership in SRPT or EDIT?

Which has higher valuation & earnings, SRPT or EDIT?

Do analysts prefer SRPT or EDIT?

Is SRPT or EDIT more profitable?

Does the media refer more to SRPT or EDIT?

Summary

How does Sarepta Therapeutics compare to Immunovant?

Which has more risk and volatility, SRPT or IMVT?

Do analysts prefer SRPT or IMVT?

Which has preferable earnings and valuation, SRPT or IMVT?

Do insiders & institutionals hold more shares of SRPT or IMVT?

Does the media refer more to SRPT or IMVT?

Is SRPT or IMVT more profitable?

Summary

How does Sarepta Therapeutics compare to Vaxcyte?

Which has better valuation & earnings, PCVX or SRPT?

Which has more volatility & risk, PCVX or SRPT?

Do insiders and institutionals hold more shares of PCVX or SRPT?

Does the media prefer PCVX or SRPT?

Do analysts recommend PCVX or SRPT?

Is PCVX or SRPT more profitable?

Summary

How does Sarepta Therapeutics compare to Lantheus?

Does the media favor SRPT or LNTH?

Is SRPT or LNTH more profitable?

Which has preferable earnings & valuation, SRPT or LNTH?

Do insiders & institutionals have more ownership in SRPT or LNTH?

Do analysts rate SRPT or LNTH?

Which has more volatility & risk, SRPT or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools